European Biotechnology Magazine Spring 2024

Berlin, 7 March 2024 – Radiopharmaceuticals have become a hot commodity in M&A financing and deals. Targeted therapies, which couple high-energy radiation with antibodies, small molecules, or peptides, promise fewer side effects and a focused attack on tumours. Novartis paved the way with an innovation from France. Now, investors are racing to follow suit, driving strong demand for start-ups. The companies involved range from tool manufacturers to those prospecting for radioactive gold.

In this issue:

• Novel Breeding Techniques: Final stretch for the European NGT regulation on climate-adapted crops
• Agreement on Antimicrobial Resistance: Novo Nordisk Foundation invests €25 million in CARB-X
• Reducing Emissions from Heavy Commercial Vehicles: A chance for e-fuels and biofuels
• The Rise of Bioplastics
• Funding for Developing New Bioprocesses
• Novartis Acquires Former Antibody Specialist MorphoSys AG in a €2.7 billion Deal

Read the latest issue here.